跳至主要内容
临床试验/ITMCTR2100005333
ITMCTR2100005333尚未招募1 期

A multicenter, randomized controlled, double-blind and double simulated clinical evaluation of gandouling tablet in the treatment of patients with hepatolenticular degeneration

The First Affiliated Hospital of Anhui University of traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
15 至 85(—)
性别
All

入选标准

  • (1) Comply with the diagnosis of hepatolenticular degeneration Guidelines for Diagnosis and Treatment of Hepatolenticular Degeneration 2021; the diagnosis of TCM syndromes complies with the syndrome of phlegm and blood stasis; Other copper-removing drugs; (3) Patients who have been treated with complexing agents for copper-removing treatment can enter the study after a 2-week washout period; (4) Age =15 years; (5) Informed consent of patients or legal representatives, And sign the informed consent form.

排除标准

  • (1) Severe cerebral WD patients: obvious torsion spasm, dysphagia, or bed rest and other severe neurological impairment will interfere with the safety of the subjects (UWDRS Part I neurological function score =156 points); (2) Severe liver Type WD patients: Decompensated liver cirrhosis or liver cancer, manifested as portal hypertension, ascites, splenomegaly (WBC<3.0*109/L, PLT<50*1012/L), esophageal varices, gastrointestinal bleeding, Moderate to severe anemia or hepatic encephalopathy; severe liver fibrosis shown by imaging or any laboratory abnormality (UWDRS liver function score = 17 points); (3) moderate to severe depression, recent suicidal thoughts or behavior, Severe psychiatric symptoms (UWDRS Part III Psychiatric Symptom Score = 54 points); (4) History of epileptic seizures within 6 months; (5) Complicated with serious diseases such as brain tumors, brain trauma, blood diseases, Cardiogenic diseases, HIV, etc.; (6) Nephritis, nephrotic syndrome, or kidney disease stage 3 or more; (7) Pregnant, planned pregnancy or breastfeeding women; (8) Cognitive dysfunction MMSE=26 points; (9) Those who are currently participating in other clinical trials; (10) Cannot comply with the follow-up plan.

研究者

发起方
The First Affiliated Hospital of Anhui University of traditional Chinese Medicine

相似试验

招募中
2 期
A multicenter randomized, controlled, double-blinded trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitisG04Encephalitis, myelitis and encephalomyelitisautoimmune encephalitis
DRKS00017497Friedrich-Schiller-Universität Jena50
尚未招募
1 期
A multicenter, double-blind, randomized controlled trial on the effect of DLTM Formula on the progression of coronary calcification in patients with stable coronary heart disease
ITMCTR2024000060Xiyuan Hospital, China Academy of Chinese Medical Sciences
进行中(未招募)
1 期
A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune EncephalitisMedDRA version: 20.0Level: PTClassification code: 10072378Term: Encephalitis autoimmune Class: 100000004852autoimmune encephalitis
CTIS2024-514494-21-00Friedrich-Schiller-Universitaet Jena50
已完成
不适用
A randomized, double-blind, controlled multicenter trial for availability of carbon dioxide insufflation during ERCP for reduction of postprocedure paipancreaticobiliary disease
JPRN-UMIN000003062Department of Gastroenterology, Hokkaido University Graduate School of Medicine100
已完成
不适用
A double-blind, randomised, controlled multicentre trial of three misoprostol regimens after pretreatment with mifepristone for termination of early pregnancyPregnancy and ChildbirthAbortionInduced abortion
ISRCTN81170837DP/UNFPA/WHO/World Bank - Special Programme of Research, Development and Research Training in Human Reproduction (HRP)2,100